AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
SANTA CLARA, Calif., June 01, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, announces depth and breadth of technologies that ignite and accelerate the development of new immune-oncology drug discovery.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/71dfadf0-8256-43cd-bafb-c429a8d37457
CrownBio scientific contribution to AACR:
- Technology which engrafts human immune cells into immunocompromised animals. When tested with immune activating agents, both short-term (PBMC) and long-term (CD34+ stem cell) engraftment strategies demonstrate robust anticancer activity.
- Syngeneic models - both in vitro and in vivo data utilizing their MuScreen™ platform, a large panel of well-characterized and validated syngeneic models, employed to test the activity of immune modulating anticancer drugs.
- Utilization of RNASeq data providing expression and mutation data from 18 cell lines. Investigators leverage this data to test both targeted therapy and immune-modulatory therapy in combination, thus providing rationale for clinical investigation.
- In vivo, the MuScreen platform enables an agnostic investigation of a compound’s activity and mechanism of action. MuScreen data can be followed-up with additional pharmacology studies, such as immunophenotyping, or bioluminescent assessment of metastatic burden.
“Our diligent focus on innovation, and continued scientific advancement charter unprecedented discovery in our immuno-oncology portfolio,” said Jean-Pierre Wery, CEO of CrownBio. “The robust contribution at this year’s annual meeting of the American Association for Cancer Research, on the part of our scientific team, validates an unwavering commitment to develop therapies that will impact the way cancer is treated.”
CrownBio can be located at ASCO Booth #17071. To schedule a meeting with our scientific leadership visit: https://www.crownbio.com/asco-meeting-req
For more information on CrownBio’s commitment to furthering the field of oncology and metabolic disease drug discovery, visit https://www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries: Jody Barbeau Crown Bioscience Inc. [email protected]
